Back to Search
MILIND JAVLE, MD
MD
Medical Oncology Physician
NPI: 1831196252IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
M5776(TX)
Education
OTHER
Class of 1992
Research & Publications (20)
Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology.
PMID 19236713·J Hematol Oncol·2009
8-other
Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis.
PMID 19235592·Cancer Invest·2009
3-trial
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
PMID 18845990·Am J Clin Oncol·2008
3-trial
Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer.
PMID 17879119·Ann Surg Oncol·2007
8-other
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
PMID 17289892·Clin Cancer Res·2007
3-trial
Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen.
PMID 19540051·Int J Radiat Oncol Biol Phys·2010
8-other
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
PMID 19491904·Br J Cancer·2009
3-trial
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
PMID 18670776·Cancer Chemother Pharmacol·2009
3-trial
CD24 expression is an independent prognostic marker in cholangiocarcinoma.
PMID 17436128·J Gastrointest Surg·2007
8-other
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
PMID 17705089·Ann Surg Oncol·2007
3-trial
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
PMID 17762434·Am J Clin Oncol·2007
3-trial
Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection.
PMID 17103074·Ann Surg Oncol·2007
8-other
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
PMID 17404091·Clin Cancer Res·2007
3-trial
Malignant gastroparesis: pathogenesis and management of an underrecognized disorder.
PMID 17944143·J Support Oncol·2007
6-review
Cystic pancreatic tumors (CPT): predictors of malignant behavior.
PMID 17323335·J Surg Oncol·2007
8-other
Epidermal growth factor receptor-directed therapy in esophageal cancer.
PMID 18477853·Oncology·2007
6-review
COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival.
PMID 17146741·Ann Surg Oncol·2007
8-other
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer.
PMID 17066293·Cancer Chemother Pharmacol·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1831196252
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile